Even after convening a two-day meeting with speakers from across the health care sector to discuss how opioid prescriber education can be improved, FDA doesn’t seem any closer to determining how to mandate training – but there are some reasons to be optimistic about a 'culture' change nevertheless.
The US FDA appears no closer to determining whether and how best to implement mandatory prescriber training as part of its efforts to address the widespread misuse and abuse of opioid pain therapies.
The agency hosted a two-day meeting May 9-10 with speakers from across the health care sector and government (including federal,...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
